Metastatic ER+ Breast Cancer Clinical Trial
Official title:
[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo Estrogen Receptor Activity in Endocrine Refractory Recurrent or Metastatic Breast Cancer
Evaluate [18F]FES PET/CT uptake as a predictor of progression free survival in endocrine refractory recurrent or metastatic breast cancer patients starting a new therapy regimen including endocrine targeted therapy.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03201913 -
Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy
|
Phase 1 |